Selective Linear Peptides for MCR-1 Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for highly selective and specific melanocortin-1 receptor (MCR-1) agonist peptides for pharmaceutical applications, as existing peptides lack sufficient specificity and selectivity.
Innovation Solution
The development of linear peptides with specific structures, including various substitutions and modifications, that act as selective agonists for the melanocortin-1 receptor, formulated in different sequences such as formulas (I), (II), (III), (IV), (V), and (VI), which can be used in pharmaceutical compositions for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing peptides are used for MCR-1 activation, then therapeutic effects can be achieved, but selectivity and specificity for MCR-1 are insufficient
Solution Approach 1:
The patent applies local quality by introducing specific substitutions at defined positions within the peptide sequence. The core tetrapeptide structure (positions 6-9) is preserved for MCR-1 binding, while selective modifications at positions 1-5 and 10-13 enhance specificity. For example, substituting position 1 with D-amino acids or specific side chains (e.g., norleucine, alpha-aminoisobutyric acid) provides localized improvements in selectivity without disrupting overall MCR-1 activation capability.
Solution Approach 2:
The patent systematically varies multiple parameters including amino acid stereochemistry (L vs D), side chain chemistry (hydrophobic, hydrophilic, charged), N-terminal modifications (acyl groups, cyclic structures), and C-terminal variations. These parameter changes create a library of peptides with optimized MCR-1 selectivity. For instance, changing the N-terminal acyl group from acetyl to longer chain acyl groups or cyclic structures significantly enhances both potency and selectivity for MCR-1 over other melanocortin receptors.
2Reliability
If peptide structures are modified to improve selectivity, then MCR-1 specificity increases, but structural complexity increases
Solution Approach 1:
The patent segments the peptide into functionally distinct regions: the core tetrapeptide (positions 6-9) that binds MCR-1, the N-terminal region (positions 1-5) that modulates selectivity and potency, and the C-terminal region (positions 10-13) that influences stability and pharmacokinetics. This segmentation allows independent optimization of each region - the core structure remains simple and conserved, while modifications are confined to terminal regions, thereby managing overall complexity.
Solution Approach 2:
The patent extracts the essential MCR-1 binding motif (the tetrapeptide sequence His-DPhe-Arg-Trp at positions 6-9) and separates it from the full α-MSH structure. By focusing modifications on the N-terminal extensions rather than the core binding sequence, the invention simplifies the overall structure while maintaining specificity. The extracted core tetrapeptide can be used as a minimal active sequence, reducing complexity compared to the full 13-amino acid α-MSH.
3Reliability
If highly selective MCR-1 agonist peptides are developed, then treatment efficacy for MCR-1-mediated diseases improves, but development complexity and formulation requirements increase
Solution Approach 1:
The patent designs peptides with optimized pharmacokinetic properties that allow for short-acting, high-potency formulations. By creating peptides with rapid onset and controlled duration of action through specific amino acid selections (e.g., incorporating amino acids that enhance protease resistance or alter metabolic stability), the invention enables disposable, single-dose administrations rather than requiring complex long-term formulation strategies. The high specificity ensures that even brief exposure achieves therapeutic effect.
Data Source
AI summary
Melanocortin receptor-specific linear peptides of the formulaZ-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Y (VI)or a pharmaceutically acceptable salt thereof,where Z, Y, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, and Xaa6 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.